<DOC>
	<DOCNO>NCT02290431</DOCNO>
	<brief_summary>The purpose study evaluate efficacy safety panobinostat combination bortezomib dexamethasone Japanese patient relapsed/refractory multiple myeloma .</brief_summary>
	<brief_title>Panobinostat Combination With Bortezomib Dexamethasone Japanese Patients With Relapsed/Refractory Multiple Myeloma</brief_title>
	<detailed_description />
	<mesh_term>Multiple Myeloma</mesh_term>
	<mesh_term>Neoplasms , Plasma Cell</mesh_term>
	<mesh_term>Dexamethasone acetate</mesh_term>
	<mesh_term>Dexamethasone</mesh_term>
	<mesh_term>Dexamethasone 21-phosphate</mesh_term>
	<mesh_term>Panobinostat</mesh_term>
	<mesh_term>Bortezomib</mesh_term>
	<mesh_term>BB 1101</mesh_term>
	<criteria>Patient previous diagnosis multiple myeloma Patient require retreatment multiple myeloma Patient measurable M component serum urine study screen Primary refractory disease ( patient never reach least minor response 60 day prior therapy ) Patient treat bortezomib , reach least minor response therapy , progress within 60 day last dose Patient receive prior treatment DAC inhibitor include panobinostat Patient impair cardiac function , prolong QTc interval screening ECG Other protocoldefined inclusion/exclusion criterion may apply .</criteria>
	<gender>All</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>N/A</maximum_age>
	<verification_date>March 2017</verification_date>
	<keyword>LBH589 ,</keyword>
	<keyword>panobinostat ,</keyword>
	<keyword>bortezomib ,</keyword>
	<keyword>dexamethasone ,</keyword>
	<keyword>Phase II</keyword>
</DOC>